APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Drug for Therapeutic

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nuclear Drug for Therapeutic Market Outlook and Growth Opportunities 2026

Report ID 17401805042 January 2026190 pages

Choose your research edition.

Industry ResearchNuclear Drug for Therapeutic Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Drug for Therapeutic Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Nuclear Drug for Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Drug for Therapeutic Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Drug for Therapeutic Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Nuclear Drug for Therapeutic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nuclear Drug for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nuclear Drug for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nuclear Drug for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nuclear Drug for Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nuclear Drug for Therapeutic market include Aurobindo Pharma, China Isotope & Radiation, Curium Pharmaceuticals, Dongcheng, International Isotopes, Jubilant Radiopharma, Lantheus, Mundipharma and Q BioMed, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nuclear Drug for Therapeutic market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nuclear Drug for Therapeutic and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nuclear Drug for Therapeutic revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nuclear Drug for Therapeutic market.

Nuclear Drug for Therapeutic Segment by Company

Aurobindo Pharma

China Isotope & Radiation

Curium Pharmaceuticals

Dongcheng

International Isotopes

Jubilant Radiopharma

Lantheus

Mundipharma

Q BioMed

Bayer

Novartis

Nuclear Drug for Therapeutic Segment by Type

Iodine-131

Radium-223

Lutetium-177

Other

Nuclear Drug for Therapeutic Segment by Application

Lymphoma

Thyroid

Bone Metastasis

Other

Nuclear Drug for Therapeutic Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Nuclear Drug for Therapeutic status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nuclear Drug for Therapeutic key companies, revenue, market share, and recent developments.

3. To split the Nuclear Drug for Therapeutic breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nuclear Drug for Therapeutic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nuclear Drug for Therapeutic significant trends, drivers, influence factors in global and regions.

6. To analyze Nuclear Drug for Therapeutic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Drug for Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Drug for Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Drug for Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nuclear Drug for Therapeutic industry.

Chapter 3: Detailed analysis of Nuclear Drug for Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nuclear Drug for Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nuclear Drug for Therapeutic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nuclear Drug for Therapeutic Industry Trends Table 2. Nuclear Drug for Therapeutic Industry Drivers Table 3. Nuclear Drug for Therapeutic Industry Opportunities and Challenges Table 4. Nuclear Drug for Therapeutic Industry Restraints Table 5. Global Nuclear Drug for Therapeutic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nuclear Drug for Therapeutic Revenue Share by Company (2021-2026) Table 7. Global Nuclear Drug for Therapeutic Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nuclear Drug for Therapeutic Key Company Manufacturing Base & Headquarters Table 9. Global Nuclear Drug for Therapeutic Company, Product Type & Application Table 10. Global Nuclear Drug for Therapeutic Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nuclear Drug for Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Iodine-131 Table 15. Significant Companies of Radium-223 Table 16. Significant Companies of Lutetium-177 Table 17. Significant Companies of Other Table 18. Global Nuclear Drug for Therapeutic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Nuclear Drug for Therapeutic Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Nuclear Drug for Therapeutic Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Nuclear Drug for Therapeutic Sales Value Share by Type (2021-2026) Table 22. Global Nuclear Drug for Therapeutic Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Lymphoma Table 24. Significant Companies of Thyroid Table 25. Significant Companies of Bone Metastasis Table 26. Significant Companies of Other Table 27. Global Nuclear Drug for Therapeutic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Nuclear Drug for Therapeutic Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Nuclear Drug for Therapeutic Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Nuclear Drug for Therapeutic Sales Value Share by Application (2021-2026) Table 31. Global Nuclear Drug for Therapeutic Sales Value Share by Application (2027-2032) Table 32. Global Nuclear Drug for Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Nuclear Drug for Therapeutic Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Nuclear Drug for Therapeutic Sales Value Share by Region (2021-2026) Table 35. Global Nuclear Drug for Therapeutic Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Nuclear Drug for Therapeutic Sales Value Share by Region (2027-2032) Table 37. Global Nuclear Drug for Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Nuclear Drug for Therapeutic Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Nuclear Drug for Therapeutic Sales Value Market Share by Country (2021-2026) Table 40. Global Nuclear Drug for Therapeutic Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Nuclear Drug for Therapeutic Sales Value Market Share by Country (2027-2032) Table 42. Aurobindo Pharma Company Information Table 43. Aurobindo Pharma Business Overview Table 44. Aurobindo Pharma Nuclear Drug for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Aurobindo Pharma Nuclear Drug for Therapeutic Product Portfolio Table 46. Aurobindo Pharma Recent Development Table 47. China Isotope & Radiation Company Information Table 48. China Isotope & Radiation Business Overview Table 49. China Isotope & Radiation Nuclear Drug for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. China Isotope & Radiation Nuclear Drug for Therapeutic Product Portfolio Table 51. China Isotope & Radiation Recent Development Table 52. Curium Pharmaceuticals Company Information Table 53. Curium Pharmaceuticals Business Overview Table 54. Curium Pharmaceuticals Nuclear Drug for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Curium Pharmaceuticals Nuclear Drug for Therapeutic Product Portfolio Table 56. Curium Pharmaceuticals Recent Development Table 57. Dongcheng Company Information Table 58. Dongcheng Business Overview Table 59. Dongcheng Nuclear Drug for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Dongcheng Nuclear Drug for Therapeutic Product Portfolio Table 61. Dongcheng Recent Development Table 62. International Isotopes Company Information Table 63. International Isotopes Business Overview Table 64. International Isotopes Nuclear Drug for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. International Isotopes Nuclear Drug for Therapeutic Product Portfolio Table 66. International Isotopes Recent Development Table 67. Jubilant Radiopharma Company Information Table 68. Jubilant Radiopharma Business Overview Table 69. Jubilant Radiopharma Nuclear Drug for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Jubilant Radiopharma Nuclear Drug for Therapeutic Product Portfolio Table 71. Jubilant Radiopharma Recent Development Table 72. Lantheus Company Information Table 73. Lantheus Business Overview Table 74. Lantheus Nuclear Drug for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Lantheus Nuclear Drug for Therapeutic Product Portfolio Table 76. Lantheus Recent Development Table 77. Mundipharma Company Information Table 78. Mundipharma Business Overview Table 79. Mundipharma Nuclear Drug for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Mundipharma Nuclear Drug for Therapeutic Product Portfolio Table 81. Mundipharma Recent Development Table 82. Q BioMed Company Information Table 83. Q BioMed Business Overview Table 84. Q BioMed Nuclear Drug for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Q BioMed Nuclear Drug for Therapeutic Product Portfolio Table 86. Q BioMed Recent Development Table 87. Bayer Company Information Table 88. Bayer Business Overview Table 89. Bayer Nuclear Drug for Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Bayer Nuclear Drug for Therapeutic Product Portfolio Table 91. Bayer Recent Development Table 92. Novartis Company Information Table 93. Novartis Business Overview Table 94. Novartis Nuclear Drug for Therapeutic Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Novartis Nuclear Drug for Therapeutic Product Portfolio Table 96. Novartis Recent Development Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Nuclear Drug for Therapeutic Product Image Figure 2. Global Nuclear Drug for Therapeutic Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Drug for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 4. Global Nuclear Drug for Therapeutic Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Iodine-131 Image Figure 8. Radium-223 Image Figure 9. Lutetium-177 Image Figure 10. Other Image Figure 11. Global Nuclear Drug for Therapeutic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Nuclear Drug for Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Nuclear Drug for Therapeutic Sales Value Share by Type (2021-2032) Figure 14. Lymphoma Image Figure 15. Thyroid Image Figure 16. Bone Metastasis Image Figure 17. Other Image Figure 18. Global Nuclear Drug for Therapeutic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Nuclear Drug for Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Nuclear Drug for Therapeutic Sales Value Share by Application (2021-2032) Figure 21. Global Nuclear Drug for Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Nuclear Drug for Therapeutic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Nuclear Drug for Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 24. North America Nuclear Drug for Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Nuclear Drug for Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Nuclear Drug for Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Nuclear Drug for Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Nuclear Drug for Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Nuclear Drug for Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 30. South America Nuclear Drug for Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Nuclear Drug for Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Nuclear Drug for Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Iodine-131
  • Radium-223
  • Lutetium-177
  • Other
Applications
  • Lymphoma
  • Thyroid
  • Bone Metastasis
  • Other
Companies covered
  • Aurobindo Pharma
  • China Isotope & Radiation
  • Curium Pharmaceuticals
  • Dongcheng
  • International Isotopes
  • Jubilant Radiopharma
  • Lantheus
  • Mundipharma
  • Q BioMed
  • Bayer
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nuclear Drug for Therapeutic Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nuclear Drug for Therapeutic Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nuclear Drug for Therapeutic Market Dynamics
  1. 2.1 Nuclear Drug for Therapeutic Industry Trends
  2. 2.2 Nuclear Drug for Therapeutic Industry Drivers
  3. 2.3 Nuclear Drug for Therapeutic Industry Opportunities and Challenges
  4. 2.4 Nuclear Drug for Therapeutic Industry Restraints
3 Nuclear Drug for Therapeutic Market by Company
  1. 3.1 Global Nuclear Drug for Therapeutic Company Revenue Ranking in 2025
  2. 3.2 Global Nuclear Drug for Therapeutic Revenue by Company (2021-2026)
  3. 3.3 Global Nuclear Drug for Therapeutic Company Ranking (2024-2026)
  4. 3.4 Global Nuclear Drug for Therapeutic Company Manufacturing Base and Headquarters
  5. 3.5 Global Nuclear Drug for Therapeutic Company Product Type and Application
  6. 3.6 Global Nuclear Drug for Therapeutic Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nuclear Drug for Therapeutic Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nuclear Drug for Therapeutic Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nuclear Drug for Therapeutic Market by Type
  1. 4.1 Nuclear Drug for Therapeutic Type Introduction
  2. 4.1.1 Iodine-131
  3. 4.1.2 Radium-223
  4. 4.1.3 Lutetium-177
  5. 4.1.4 Other
  6. 4.2 Global Nuclear Drug for Therapeutic Sales Value by Type
  7. 4.2.1 Global Nuclear Drug for Therapeutic Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Nuclear Drug for Therapeutic Sales Value by Type (2021-2032)
  9. 4.2.3 Global Nuclear Drug for Therapeutic Sales Value Share by Type (2021-2032)
5 Nuclear Drug for Therapeutic Market by Application
  1. 5.1 Nuclear Drug for Therapeutic Application Introduction
  2. 5.1.1 Lymphoma
  3. 5.1.2 Thyroid
  4. 5.1.3 Bone Metastasis
  5. 5.1.4 Other
  6. 5.2 Global Nuclear Drug for Therapeutic Sales Value by Application
  7. 5.2.1 Global Nuclear Drug for Therapeutic Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Nuclear Drug for Therapeutic Sales Value by Application (2021-2032)
  9. 5.2.3 Global Nuclear Drug for Therapeutic Sales Value Share by Application (2021-2032)
6 Nuclear Drug for Therapeutic Regional Value Analysis
  1. 6.1 Global Nuclear Drug for Therapeutic Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nuclear Drug for Therapeutic Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nuclear Drug for Therapeutic Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nuclear Drug for Therapeutic Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nuclear Drug for Therapeutic Sales Value (2021-2032)
  7. 6.3.2 North America Nuclear Drug for Therapeutic Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nuclear Drug for Therapeutic Sales Value (2021-2032)
  10. 6.4.2 Europe Nuclear Drug for Therapeutic Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nuclear Drug for Therapeutic Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nuclear Drug for Therapeutic Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nuclear Drug for Therapeutic Sales Value (2021-2032)
  16. 6.6.2 South America Nuclear Drug for Therapeutic Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nuclear Drug for Therapeutic Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nuclear Drug for Therapeutic Sales Value Share by Country, 2025 VS 2032
7 Nuclear Drug for Therapeutic Country-level Value Analysis
  1. 7.1 Global Nuclear Drug for Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nuclear Drug for Therapeutic Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nuclear Drug for Therapeutic Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nuclear Drug for Therapeutic Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nuclear Drug for Therapeutic Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nuclear Drug for Therapeutic Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nuclear Drug for Therapeutic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aurobindo Pharma
  2. 8.1.1 Aurobindo Pharma Company Information
  3. 8.1.2 Aurobindo Pharma Business Overview
  4. 8.1.3 Aurobindo Pharma Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aurobindo Pharma Nuclear Drug for Therapeutic Product Portfolio
  6. 8.1.5 Aurobindo Pharma Recent Developments
  7. 8.2 China Isotope & Radiation
  8. 8.2.1 China Isotope & Radiation Company Information
  9. 8.2.2 China Isotope & Radiation Business Overview
  10. 8.2.3 China Isotope & Radiation Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  11. 8.2.4 China Isotope & Radiation Nuclear Drug for Therapeutic Product Portfolio
  12. 8.2.5 China Isotope & Radiation Recent Developments
  13. 8.3 Curium Pharmaceuticals
  14. 8.3.1 Curium Pharmaceuticals Company Information
  15. 8.3.2 Curium Pharmaceuticals Business Overview
  16. 8.3.3 Curium Pharmaceuticals Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Curium Pharmaceuticals Nuclear Drug for Therapeutic Product Portfolio
  18. 8.3.5 Curium Pharmaceuticals Recent Developments
  19. 8.4 Dongcheng
  20. 8.4.1 Dongcheng Company Information
  21. 8.4.2 Dongcheng Business Overview
  22. 8.4.3 Dongcheng Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Dongcheng Nuclear Drug for Therapeutic Product Portfolio
  24. 8.4.5 Dongcheng Recent Developments
  25. 8.5 International Isotopes
  26. 8.5.1 International Isotopes Company Information
  27. 8.5.2 International Isotopes Business Overview
  28. 8.5.3 International Isotopes Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  29. 8.5.4 International Isotopes Nuclear Drug for Therapeutic Product Portfolio
  30. 8.5.5 International Isotopes Recent Developments
  31. 8.6 Jubilant Radiopharma
  32. 8.6.1 Jubilant Radiopharma Company Information
  33. 8.6.2 Jubilant Radiopharma Business Overview
  34. 8.6.3 Jubilant Radiopharma Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jubilant Radiopharma Nuclear Drug for Therapeutic Product Portfolio
  36. 8.6.5 Jubilant Radiopharma Recent Developments
  37. 8.7 Lantheus
  38. 8.7.1 Lantheus Company Information
  39. 8.7.2 Lantheus Business Overview
  40. 8.7.3 Lantheus Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lantheus Nuclear Drug for Therapeutic Product Portfolio
  42. 8.7.5 Lantheus Recent Developments
  43. 8.8 Mundipharma
  44. 8.8.1 Mundipharma Company Information
  45. 8.8.2 Mundipharma Business Overview
  46. 8.8.3 Mundipharma Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mundipharma Nuclear Drug for Therapeutic Product Portfolio
  48. 8.8.5 Mundipharma Recent Developments
  49. 8.9 Q BioMed
  50. 8.9.1 Q BioMed Company Information
  51. 8.9.2 Q BioMed Business Overview
  52. 8.9.3 Q BioMed Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Q BioMed Nuclear Drug for Therapeutic Product Portfolio
  54. 8.9.5 Q BioMed Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bayer Nuclear Drug for Therapeutic Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 Novartis
  62. 8.11.1 Novartis Company Information
  63. 8.11.2 Novartis Business Overview
  64. 8.11.3 Novartis Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis Nuclear Drug for Therapeutic Product Portfolio
  66. 8.11.5 Novartis Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst